Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2013 Credit Suisse Healthcare Conference

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2013
Credit Suisse Healthcare Conference

BETHESDA, Md., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc.
("Sucampo") (Nasdaq:SCMP), a global biopharmaceutical company, today announced
that it will webcast its corporate presentation at the 2013 Credit Suisse
Healthcare Conference on Wednesday, November 13, 2013, at 4:00 pm Mountain, or
6:00 pm Eastern.

The presentation will be webcast live and may be accessed from the Event
Calendar page of Sucampo's website at
http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar.
Presentation slides will be available via the webcast link. A replay of the
webcast will also be available on Sucampo's website for several days after the
live event. To ensure a timely connection, it is recommended that users
register at least 15 minutes prior to the scheduled webcast.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is focused on the discovery, development and
commercialization of drugs based on ion channel activators knows as prostones.
Discovered by the company's scientific founder, prostones are naturally
occurring fatty acid metabolites with unique physiological activities. Sucampo
has two marketed products – AMITIZA® and RESCULA® – and a pipeline of
prostone-based product candidates in clinical development. A global company,
Sucampo is headquartered in Bethesda, Maryland, and has operations in the
United Kingdom, Switzerland and Japan. For more information, please visit
www.sucampo.com.

The Sucampo logo and the tagline, The Science of Innovation, are registered
trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo
AG.RESCULA is a registered trademark of R-Tech Ueno, Ltd, and has been
licensed to Sucampo AG.

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of
pharmaceutical industry regulation and health care legislation; Sucampo's
ability to accurately predict future market conditions; dependence on the
effectiveness of Sucampo's patents and other protections for innovative
products; the risk of new and changing regulation and health policies in the
U.S. and internationally and the exposure to litigation and/or regulatory
actions. No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Sucampo undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new
information, future events, or otherwise. Forward-looking statements in this
presentation should be evaluated together with the many uncertainties that
affect Sucampo's business, particularly those mentioned in the risk factors
and cautionary statements in Sucampo's most recent Form 8-K and 10-K, which
Sucampo incorporates by reference.

Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo
Pharmaceuticals).

Twitter LinkedIn

CONTACT: Silvia Taylor
         Senior Vice President, IR, PR, and Corporate Communications
         1-240-223-3718
         staylor@sucampo.com

Sucampo Logo